Plus Therapeutics subsidiary receives clinical lab accreditation

Plus Therapeutics Inc. (NASDAQ: PSTV) announced that its wholly-owned subsidiary CNSide Diagnostics received accreditation from the Centers for Medicare and Medicaid Services for its Houston laboratory. The certification confirms compliance with Clinical Laboratory Improvement Amendments regulations, which establish federal standards for laboratories testing human specimens.

The accreditation enables CNSide Diagnostics to pursue state licensure in 48 of 50 states and access commercial insurance coverage for its CNSide cerebrospinal fluid assay platform. The certification also allows the laboratory to enroll in Medicare and Medicaid programs and pursue unique reimbursement billing codes.

"This is a key milestone on our trajectory to bring the CNSide cerebrospinal fluid assay platform to the broadest possible set of patients with or at risk for CNS cancers," said Russ Bradley, president and general manager of CNSide Diagnostics.

CNSide Diagnostics develops laboratory tests designed to identify tumor cells that have spread to the central nervous system in patients with carcinomas and melanomas. The CNSide assay platform analyzes tumor cells and circulating tumor DNA in cerebrospinal fluid to help manage patients with leptomeningeal metastases.

Plus Therapeutics is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for central nervous system cancers. The company's pipeline includes programs targeting leptomeningeal metastases and recurrent glioblastoma.

The information is based on a company press release.

You May Also Be Interested In

• Boeing names Ryan Shedd as new SVP and controller
• loanDepot receives NYSE non-compliance notice over stock price
• Alzamend Neuro (ALZN) files for 98.4M share offering by selling stockholders